

IN THIS ISSUE

RDTC Focus: NHS Medicines Optimisation Opportunities Dashboard 2023/24	1
Recent publications from the RDTC	1
Latest prescribing news from your area	2
Meet the RDTC Team	2
RDTC website: New features	2
Strategic Insight: Defining the type-2 diabetic population	2
Serious shortage protocols (SSPs)	3
Medicines Availability Information	3
Dates for your Diary: RDTC reports, publications, resources demo and Q&A sessions.	3

RDTC Focus: NHS Medicines Optimisation Opportunities Dashboard 2023/24

The RDTC [MO opportunities dashboard](#) presents both the single NHSE metric (found on ePACT2) alongside a suite of additional metrics, trend charts and bar charts to support understanding, deep dive and monitoring against the 16 MO opportunities identified in the [National Guidance](#).

The RDTC supporting metrics are tailored for the population demographics of the North of England and cover both primary and secondary care medicines data and spend. The RDTC dashboard is currently available to all NHS colleagues working in ICBs in the North of England, with supporting resources remaining accessible to RDTC NHS stakeholders only. For instance, the MO opportunity 'Improving respiratory outcomes while reducing carbon emissions from inhalers' includes the national metric 'Mean inhaler emissions per patient', this is supported by RDTC metrics for 'Mean inhaler emissions per patient adjusted for the relative Asthma & COPD prevalence, total inhaler emissions and progress against NHS LTP target (50% reduction), hospital admissions for COPD & Asthma to reflect the aim of improving respiratory outcomes' and links to RDTC stakeholder supporting resources (available on the website): Therapeutic report (respiratory), Cost comparison charts (Inhalers), Medicines in practice (Inhaler sustainability), Prescribing bulletins (Inhaler disposal), Prescribing for population health (Significance focus action) and the Inhaler carbon impact assessment tool (updated to include Oct 22-Sept 23 prescribing data).

The MO opportunities dashboard metrics continue to be developed to reflect feedback and needs as they are identified. Furthermore, incorporation of additional secondary care data to support metrics on medicines value and commercial medicines frameworks, is still in progress. Work is also ongoing to re-design some of the metrics for interpretation at SICBL. For instance, the Items of low clinical value report (Region, ICB and SICBL) has been updated to reflect the latest NHSE guidance (August 2023) and will be published on the RDTC website in Jan 2024.

For further information about the RDTC MO Dashboard, or to request support, please contact the prescribing support team nuth.nyrdtc.rxsupp@nhs.net.

Recent publications from the RDTC

Medicines Optimisation:

- [National medicines optimisation opportunities dashboard 2023/24](#)

Monthly Formulary Amendments:

- [September, October, November](#)

Monthly Horizon Scanning:

- [October, November, December](#)

Strategic Insight

- [Defining the type-2 diabetic population: a first step to understanding the impact of pathway choices](#)

Prescribing Analysis Reports:

- [Monthly Financial Headlines \(September 2023\)](#)
- [Drug Tariff Monitor \(October 2023\)](#)
- [Cost Comparison Chart \(October 2023\)](#)
- [Price concession bulletin \(October 2023\)](#)
- [Top 50 BNF Sections and Drugs Report \(April to September 2023\)](#)

Therapeutic reports

- [Dementia](#) (Q1,2,3 & 4 22/23)
- [Diabetes](#) (Q1,2,3 & 4 22/23)
- [Antibacterial](#) (Q1,2,3 & 4 22/23)
- [Cardiovascular](#) (Q1,2,3 & 4 22/23)
- [Respiratory](#) (Q1,2,3 & 4 22/23)
- [Pain](#) (Q1,2,3 & 4 22/23)



@RDTC_Rx



Latest prescribing news from your area

To access formulary decision summaries from your local formulary committee, see:

- [North Yorkshire and York Area Prescribing Committee](#)
- [Greater Manchester Medicines Management Group](#)
- [Humber APC](#)
- [NENC Medicines Committee](#)

Meet the RDTC Team

In each newsletter we are going to introduce one of the members of the RDTC team and how they support your work.

This edition focuses on Maxine Wright - Medical Information Scientist

"I suppose it had to be my turn soon enough, seeing as I have been chasing all my colleagues for their biographies for the last 18 months! Part of my remit at the RDTC is to curate this marvellous newsletter, as well as support the prescribing team with up-to-date information via regular publications such as the Monthly horizon scanning and the Monthly formulary amendments documents. There is also responding to requests from our ICB stakeholders regarding new products which are being considered for inclusion on formularies that we support. I came to the RDTC via a rather circuitous route - hospital pharmacy as a technician, medical software clinical support and a Biomedical Sciences degree. I hope that all these past experiences assist me to do the best for you! When I'm not at work I'm often found at the beach with the dog, marshalling at parkrun or am-dramming it up in some daft costume (hence the picture - not normal day wear!)"




Have an idea for a new document?

If you need a report, document, or prescribing data that we don't already produce, get in touch at nuth.nyrdtc.rxsupp@nhs.net or tweet us at [@RDTC Rx](https://twitter.com/RDTC_Rx)

RDTC website: New features

Two new topics have been added to the RDTC website: Sustainability and Research.



Strategic Insight:

Defining the type-2 diabetic population: a first step to understanding the impact of pathway choices

The prevalence of diabetes in England has increased markedly in the last decade with 3,625,401 people registered with diabetes in England in 2021/22 compared with 2,566,436 at the end of 2011/12, representing a 41% absolute increase.

Prescribing medication to people with diabetes in general practice is now the single biggest cost area for prescribing in NHS England, with 60.3 million items for drugs used in diabetes prescribed in England in 2021/22, at a cost of £1.25 billion.

This [Strategic Insight](#) document aims to determine current prescribing patterns and prescribing costs of antidiabetic treatments across the ICBs in the North of England with a particular emphasis on SGLT-2 inhibitors and GLP-1 mimetics. This will enable organisations to audit current practices against updated NICE guideline recommendations, and to estimate the financial and resource implications of prescribing SGLT-2s to a wider population.

A forthcoming addendum to this publication will estimate the gap between current prescribing of SGLT-2 inhibitors and the number of people with type 2 diabetes who are estimated to be eligible for treatment. Three versions of this addendum will be published covering the North East and Cumbria, Greater Manchester, and Yorkshire and the Humber regions.





Serious shortage protocols (SSPs)

Drug involved	Start and End Date of SSP
Clarithromycin 125mg/5ml, 250mg/5 ml oral suspension	Start: 06/04/2023 Expiry: 12/01/2024

For all new and updated NICE guidance, including safety alerts, please see our regular [Monthly Formulary Amendments document](#)

Details of all national shortages can be found on the [SPS website](#). Registration is required.

Primary care MI enquiries: 0300 7708564 or email asksp.nhs@sps.direct

Medicines Availability Information

[Bumetanide 1mg and 5mg tablets](#) are anticipated to be available from 5/1/2024 and 8/3/2024 respectively. Healthcare professionals in primary and secondary care should not initiate any new patients on bumetanide until the supply issue has resolved. For existing patients, a switch should be made before patients run out of tablets to avoid a break in therapy that could increase the risk of decompensation and unintentional fluid retention.

[Flixonase Nasal Drops](#) are being discontinued, with stock exhausted by the end of December 2023. Generic fluticasone 400microgram/unit dose nasal drops (Aspire Pharma) are in limited supply until early February 2024. Betamethasone 0.1% nose drops remain available and can support increased demand. Mometasone 50micrograms/dose nasal spray remains available but cannot support an uplift in demand.

Dates for your Diary: RDTC reports, publications, resources demo and Q&A sessions

We are offering 1 hour MS Teams sessions (10-11am) for NHS colleagues to attend a relaxed demo of RDTC resources. We'll bring a few of the RDTC team; analysts, scientists and pharmacists, you're welcome to bring a cuppa. We aim to spend a third of the session supporting more in-depth discussion of topics of interest and answering your questions.

30th January: Medicines value & financial reports; Drug tariff monitor, Monthly financial headlines, Price concessions, Top 50, Growth contrast tool, Cost comparison charts, Medicines value bulletins & tracker, Low clinical value items report, Medicines Optimisation opportunities dashboard.

12th March: Respiratory & sustainability; Therapeutic report (respiratory), Cost comparison charts (Inhalers), Medicines in practice (Inhaler sustainability), Prescribing bulletins (Inhaler disposal), Prescribing for population health (Significance focus action), Inhaler carbon impact assessment tool, Medicines value bulletins & tracker (carbocisteine), Medicines Optimisation opportunities dashboard, Research.

21st May: Diabetes, including managed entry of meds; Therapeutic report (Diabetes), Cost comparison charts (BG test strips), Strategic Insight (T2DM population) & addendum, New drug evaluations/Evaluation report, Medicines Optimisation opportunities dashboard, Medicines value bulletins & tracker (metformin), Prescribing for population health (insulin pumps), Formulary assessment tools, Formulary amendments, Monthly horizon scanning.

16th July: Medicines safety & population health management: Shared care protocols, Medicines Optimisation opportunities dashboard (valproate, polypharmacy, opioids), Comparison tables (DOACs), Safer medication use (propranolol), Antimicrobial therapeutic report, Prescribing bulletins (Antibiotic use in children), Prescribing for population health (Antibiotics & AWaRe).

To book your place and receive your MS Teams link, please email: nuth.nyrdtc.rxsupp@nhs.net with the details of the session(s) you would like to attend.

If you are unable to attend on the date/time available but would like to, please email to discuss alternative options.

Looking for something?

Our documents, reports, and other useful publications are all published on our website www.rdtc.nhs.uk

Drafts may be available on request

We need YOU!

We're always on the lookout for reviewers to comment on our draft publications. If you'd be interested [email us](#) and we'll add you to our reviewers list.

Specialise in a particular area?

We can tailor what we send you for review so that you only receive documents relevant to you

THIS NEWSLETTER IS PRODUCED BY THE NHS FOR THE NHS:
NOT TO BE USED FOR COMMERCIAL PURPOSES